Daily non-political popular news in brief.
Efficacy and safety of Aripiprazole as adjunctive therapy in major depressive disorder
05-22-2007 · EurekAlert!A study presented today at the 160th Annual Meeting of the American Psychiatric Association showed that, in adults with major depressive disorder, adding ABILIFY(R)(aripiprazole) to antidepressant therapy resulted in significant improvement in the primary endpoint, the MADRS Total Score. A reduction in MADRS Total Score represents improvement in depressive symptoms.
Read more »
Keywords: efficacy, safety, aripiprazole, adjunctive, therapy, major, depressive, disorder
« Previous | Next »
Similar news on "Efficacy and safety of Aripiprazole as adjunctive therapy in major depressive disorder":
- Adding medication improves recovery for elderly with depression, says Pitt School of Medicine study
06-01-2007 · EurekAlert!
Adding a medication to a standard treatment regimen for major depressive disorder in the elderly improves chances of recovery in those who do not adequately respond to the first-course therapy or who relapse from it, finds a University of Pittsburgh School of Medicine study published in the June issue of the American Journal of Psychiatry.
Similar news · Read more »
- Double trouble: Hopelessness key component of mood disorder
07-23-2007 · EurekAlert!
Double depression occurs when an individual who suffers from dysthymia, a persistent case of mild depression marked by low energy, falls into a major depressive state. It is not a new concept, but psychologists know little about the characteristics that distinguish double depression from dysthymia or major depression alone, according to Joiner.
Similar news · Read more »
- Cow protein aids in treatment of gastrointestinal disorder
05-16-2007 · EurekAlert!
Recent evidence suggests that therapy currently used to treat Helicobacter pylori (H. pylori) infection, a major cause of upper gastrointestinal disorders, is unsuccessful in around 25 percent of cases. A new study, published in The American Journal of Gastroenterology, finds that adding a bovine protein called lactoferrin to the existing treatment may yield more effective results, with fewer of the side effects associated with common antibiotic treatment.
Similar news · Read more »
- Enbrel first biologic with up to 9 years rheumatoid arthritis safety, sustained efficacy data
11-13-2006 · EurekAlert!
Amgen (NASDAQ: AMGN) announced Enbrel (R) (etanercept) is the first biologic with published data to show sustained improvements in multiple efficacy measures in rheumatoid arthritis patients completing up to nine years of therapy. Current data suggest Enbrel is both effective and safe in long-term RA use, and the new data, presented at the American College of Rheumatology scientific meeting, provide a degree of reassurance that unexpected safety concerns do not appear to develop after nine years of use.
Similar news · Read more »
- Tips from the Journals of the American Society for Microbiology
08-20-2007 · EurekAlert!
In this issue: "Phage Therapy May Control Staph Infections in Humans Including MRSA"; "New Smallpox Vaccine Candidates Demonstrate Superior Immune Response, Efficacy and Safety in Mice"; and "First Animal Model Developed for Oral Infection of Human Poliovirus."
Similar news · Read more »
- Depressed adolescents respond best to combination treatment
10-01-2007 · EurekAlert!
A combination of psychotherapy and antidepressant medication appears to be the most effective treatment for adolescents with major depressive disorder -- more than medication alone or psychotherapy alone, according to results from a major clinical trial funded by the National Institutes of Health's National Institute of Mental Health.
Similar news · Read more »
- JAMA: Study finds benefits of antidepressants in treating pediatric depression
04-17-2007 · EurekAlert!
According to a new study, conducted by the Center for Innovation in Pediatric Practice at Columbus Children's Hospital and published in the April 18 issue of the Journal of the American Medical Association, the overall benefits of antidepressants in treating pediatric major depressive disorder, obsessive-compulsive disorder and non-OCD anxiety disorders in children 19-years-old and younger clearly out-weigh the risks of suicidal thoughts and attempts associated with these medications.
Similar news · Read more »
- Novel platelet therapy may reduce PCI complications
03-24-2007 · EurekAlert!
Despite the availability of numerous antithrombotic therapies, adverse events following percutaneous coronary intervention such as late-stent thrombosis are still a concern for cardiologists, and there's a need for medications that can minimize the risk of these complications but also manage the rate of bleeding. A study presented today at the American College of Cardiology's Innovation in Intervention: i2 Summit evaluates the safety and efficacy of a novel oral thrombin receptor antagonist in reducing PCI complications.
Similar news · Read more »
- Antidepressants safe for children and adolescents
04-17-2007 · EurekAlert!
Antidepressants are safe and effective for treating anxiety, OCD and major depressive disorder in children and adolescents, according to a meta-analysis of 27 major studies. The findings, published by University of Pittsburgh School of Medicine researchers in this week's JAMA, call into question the controversial "black box" warnings placed on the drugs by the FDA, which say antidepressant medications pose a small but significantly increased risk of suicidal thoughts and behavior for children and adolescents.
Similar news · Read more »
- Venlafaxine extended-release effective for patients with major depression
12-12-2007 · EurekAlert!
Major depressive disorder is the most common major mental illness, afflicting almost one in five individuals. More than 75 percent of people who recover from an episode of MDD will have at least one recurrence, with the majority having multiple recurrences.
Similar news · Read more »
